Key result
Dexmedetomidine 1μg/kg significantly attenuated the hyperdynamic response to ECT, resulting in a lower mean heart rate immediately post-ECT compared to placebo (78.43 vs 98.5 bpm, p<0.001), without affecting seizure duration.
Why the study?
Does dexmedetomidine reduce the hemodynamic stress response in patients undergoing modified electroconvulsive therapy?
RCT (n=60)
Double-blind
Sealed envelopes
No
Does dexmedetomidine reduce the hemodynamic stress response in patients undergoing modified electroconvulsive therapy?
Absolute Event Rate: 78.43% vs 98.5%
p-value: p=<0.001
Dexmedetomidine 1µg/kg effectively attenuates the hyperdynamic cardiovascular response to electroconvulsive therapy without compromising seizure duration or prolonging recovery.
Supports dexmedetomidine 1 μg/kg to blunt ECT tachycardia safely; extends anesthesia evidence to modified ECT without seizure compromise.
Background: Modified electroconvulsive therapy (ECT) under anesthesia is an important modality in the treatment of severe, persistent depression; bipolar disorder and schizophrenia; especially in cases resistant to pharmacologic therapy.
No takes yet. Share an insight, caveat, or question.
Garg et al. (2018) conducted an RCT in Severe depression, schizophrenia, catatonia, or bipolar disorder requiring ECT (n=60). Dexmedetomidine vs. Normal saline (placebo) was evaluated on Mean heart rate immediately after ECT (0 min) (p=<0.001). Dexmedetomidine 1μg/kg significantly attenuated the hyperdynamic response to ECT, resulting in a lower mean heart rate immediately post-ECT compared to placebo (78.43 vs 98.5 bpm, p<0.001), without affecting seizure duration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: